Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Division of Neonatology, Children's Hospital of Philadelphia Newborn Care at Pennsylvania Hospital, Philadelphia.
JAMA Pediatr. 2021 Feb 1;175(2):168-175. doi: 10.1001/jamapediatrics.2020.4719.
Escherichia coli is a leading cause of serious infection among term and preterm newborn infants. Surveillance of antibiotic susceptibility patterns of E coli among infants admitted to neonatal intensive care units should inform empirical antibiotic administration.
To assess the epidemiologic characteristics and antibiotic susceptibility patterns of E coli in infants admitted to neonatal intensive care units in the US over time.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used the Premier Health Database, a comprehensive administrative database of inpatient encounters from academic and community hospitals across the US. Participants included newborn infants admitted to centers contributing microbiology data from January 1, 2009, to December 31, 2017, with E coli isolated from blood, cerebrospinal fluid, or urine cultures. Data were collected and analyzed from December 1, 2018, to November 30, 2019.
Changes in annual antibiotic susceptibility of E coli during the study period. The proportion of infants with nonsusceptible organisms (resistant or intermediate susceptibility) in antibiotic categories by year, birth weight, infection source, and timing of infection and patient and center characteristics associated with neonatal E coli infection and antibiotic susceptibility were assessed.
A total of 721 infants (434 male [60.2%]; median age at E coli infection, 14 days [interquartile range, 1-33 days]) from 69 centers had at least 1 episode of E coli infection and available susceptibility results. No significant changes were observed over time in the overall annual proportions of antibiotic nonsusceptibility to ampicillin (mean [SD], 66.8% [1.5%]; range, 63.3% to 68.6%; estimated yearly change, -0.28% [95% CI, -1.75% to 1.18%]), nonsusceptibility to aminoglycosides (mean [SD], 16.8% [4.5%]; range, 10.7% to 23.2%; estimated yearly change, -0.85% [95% CI, -1.93% to 0.23%]), or extended-spectrum β-lactamase phenotype (mean [SD], 5.0% [3.7%]; range, 0% to 11.1%; estimated yearly change, 0.46% [95% CI, -0.18% to 1.11%]). No isolates with nonsusceptibility to carbapenems were identified. Among 218 infants with early-onset infection, 22 (10.1%) had isolates with nonsusceptibility to both ampicillin and gentamicin, the antibiotics most commonly administered to newborns as empirical therapy.
In this cohort study, nonsusceptibility to commonly administered antibiotics was found in substantial proportions of neonatal E coli isolates, with no significant change from 2009 to 2017. These findings may inform empirical antibiotic choices for newborn infants.
大肠杆菌是导致足月和早产儿严重感染的主要原因。监测新生儿重症监护病房中大肠杆菌的抗生素药敏模式,应能为经验性抗生素治疗提供信息。
评估美国新生儿重症监护病房中大肠杆菌的流行病学特征和抗生素药敏模式随时间的变化。
设计、地点和参与者:本回顾性队列研究使用了 Premier Health Database,这是一个来自美国学术和社区医院的综合住院患者数据行政数据库。参与者包括 2009 年 1 月 1 日至 2017 年 12 月 31 日期间从血液、脑脊液或尿液培养物中分离出大肠杆菌的中心入院的新生儿。数据于 2018 年 12 月 1 日至 2019 年 11 月 30 日收集和分析。
在研究期间大肠杆菌抗生素药敏性的年度变化。按年份、出生体重、感染源、感染时间以及与新生儿大肠杆菌感染和抗生素药敏性相关的患者和中心特征,评估了抗生素类别中对非敏感菌(耐药或中介敏感)的婴儿比例。
共有 69 个中心的 721 名婴儿(434 名男性[60.2%];大肠杆菌感染的中位年龄为 14 天[四分位间距,1-33 天])至少有 1 次大肠杆菌感染和可用的药敏结果。在整个研究期间,对氨苄西林(总体年抗生素不敏感比例,66.8%[1.5%];范围,63.3%至 68.6%;估计每年变化,-0.28%[95%置信区间,-1.75%至 1.18%])、氨基糖苷类药物(16.8%[4.5%];范围,10.7%至 23.2%;估计每年变化,-0.85%[95%置信区间,-1.93%至 0.23%])或扩展谱β-内酰胺酶表型(5.0%[3.7%];范围,0%至 11.1%;估计每年变化,0.46%[95%置信区间,-0.18%至 1.11%])的不敏感比例没有明显变化。未发现对碳青霉烯类药物不敏感的分离株。在 218 名早发性感染的婴儿中,有 22 名(10.1%)对氨苄西林和庆大霉素均不敏感,这两种抗生素是新生儿经验性治疗中最常使用的抗生素。
在这项队列研究中,新生儿大肠杆菌分离株中发现了相当比例的常见抗生素不敏感,2009 年至 2017 年期间没有明显变化。这些发现可能为新生儿提供经验性抗生素治疗选择。